Product diversity has helped the company maintain strengths in a variety of
therapeutic areas. Pharmacia & Upjohn
offers leading products in specialist areas such as oncology, ophthalmology, and metabolic
disorders. The company also provides a broad
range of antibiotics, helping to meet an important need in the largest segment of the
Philippine pharmaceutical market.
The future promises many opportunities for Pharmacia & Upjohn as the
pharmaceutical market and patient needs continue to evolve.
In response to the rising incidence of diabetes, Pharmacia & Upjohn is
developing its diabetes franchise.
To address increasing levels of heart disease, the company will seek
approval for the use of Fragmin® (dalteparin sodium) to trat unstable coronary
artery disease - a new indication for the product.
Pharmacia & Upjohn has developed a solid clinical research base to
help facilitate the introduction of medicines. Xalatan®, the breakthrough treatment for glaucoma, was
recently launched in the Philippines. The
product line will be further expanded with the introduction of new products to treat
cataract and infections.
